FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2992887668> ?p ?o ?g. }

• W2992887668 endingPage "e41" @default.
• W2992887668 startingPage "e31" @default.
• W2992887668 abstract "Background Glucocorticoids are highly effective and widely used anti-inflammatory drugs, but their use is limited by serious side-effects, including glucocorticoid-induced hyperglycaemia and diabetes. AZD9567 is a non-steroidal, selective glucocorticoid receptor modulator that aims to reduce side-effects. We aimed to assess the safety, tolerability, and pharmacokinetics of AZD9567 in healthy volunteers. Methods Two phase 1 clinical studies were done. First, a randomised, placebo-controlled, single-blind, single-ascending dose study was done in healthy men who received single oral doses of AZD9567 2 mg, 10 mg, 20 mg, 40 mg, 80 mg, 100 mg, 125 mg, or 155 mg, or prednisolone 60 mg (n=8 per dose group, randomly assigned [6:2] to receive active drug or placebo). Second, a randomised, active-controlled, single-blind, multiple-ascending dose study was done, in which men and women received oral AZD9567 or prednisolone once daily for 5 days. One cohort of volunteers with prediabetes received AZD9567 10 mg (n=7) or prednisolone 20 mg (n=2). All other cohorts comprised healthy volunteers, receiving AZD9567 20 mg, 40 mg, 80 mg, or 125 mg (n=7 per dose group), or prednisolone 5 mg (n=13), 20 mg (n=16), or 40 mg (n=13). Participants and study centre staff were masked to treatment assignment for each cohort, although data were unmasked for safety review between cohorts. The primary outcome of the single-ascending dose study was the safety, tolerability, and pharmacokinetics of single ascending doses of AZD9567; for the multiple-ascending dose study it was the safety and tolerability of AZD9567 following multiple ascending doses. As a secondary outcome, effects on glycaemic control were ascertained with oral glucose tolerance tests (OGTTs) done at baseline and on day 1 of the single-ascending dose study, and at baseline and on day 4 of the multiple-ascending dose study. These trials are registered at ClinicalTrials.gov, NCT02512575 and NCT02760316. Findings In the single-ascending dose study, between Nov 18, 2015, and Sept 26, 2016, 72 healthy white men were enrolled, and all completed the study. In the multiple-ascending dose study, between May 2, 2016, and Sept 13, 2017, 77 predominantly white male volunteers (including nine individuals with prediabetes and eight women) were enrolled and 75 completed the study. All doses of AZD9567 and prednisolone were well tolerated, with no serious adverse events or events suggesting adrenal insufficiency. In the single-ascending dose study, nine adverse events of mild intensity were reported (five with AZD9567 and four with placebo); no adverse event was reported by more than one person. In the multiple-ascending dose study, 44 adverse events of mild or moderate intensity were reported (18 with AZD9567 and 26 with prednisolone). The most common were headache and micturition. Apparent clearance, volume of distribution, and half-life of AZD9567 were consistent across doses and for single versus repeated dosing. In the multiple-ascending dose study, OGTTs showed no significant difference with AZD9567 doses up to 80 mg compared with prednisolone 5 mg in glucose area under the curve from 0 h to 4 h post-OGTT (AUC0–4h) from baseline to day 4; the increase in glucose AUC0–4h from baseline to day 4 was significantly lower with all AZD9567 doses versus prednisolone 20 mg (AZD9567 20 mg p<0·0001, 40 mg p=0·0001, 80 mg p=0·0001, and 125 mg p=0·0237). Interpretation AZD9567 appears to be safe and well tolerated in healthy, predominantly white male volunteers and shows promising initial evidence for improved post-prandial glucose control. Studies of longer duration, with a greater proportion of women and other ethnic groups, and in patients requiring anti-inflammatory treatment are needed to characterise the clinical efficacy and safety profile of AZD9567. Funding AstraZeneca." @default.
• W2992887668 created "2019-12-13" @default.
• W2992887668 creator A5001117631 @default.
• W2992887668 creator A5006313543 @default.
• W2992887668 creator A5008926411 @default.
• W2992887668 creator A5010876723 @default.
• W2992887668 creator A5014431886 @default.
• W2992887668 creator A5018416006 @default.
• W2992887668 creator A5021039420 @default.
• W2992887668 creator A5025390498 @default.
• W2992887668 creator A5029122785 @default.
• W2992887668 creator A5037371315 @default.
• W2992887668 creator A5041345164 @default.
• W2992887668 creator A5052403064 @default.
• W2992887668 creator A5053880217 @default.
• W2992887668 creator A5057927354 @default.
• W2992887668 creator A5068116173 @default.
• W2992887668 creator A5073092807 @default.
• W2992887668 creator A5079776737 @default.
• W2992887668 creator A5083850527 @default.
• W2992887668 creator A5085246518 @default.
• W2992887668 date "2020-01-01" @default.
• W2992887668 modified "2023-09-27" @default.
• W2992887668 title "Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials" @default.
• W2992887668 cites W1719124165 @default.
• W2992887668 cites W1967420703 @default.
• W2992887668 cites W1971909806 @default.
• W2992887668 cites W1974022347 @default.
• W2992887668 cites W2005229523 @default.
• W2992887668 cites W2018830028 @default.
• W2992887668 cites W2018850250 @default.
• W2992887668 cites W2040750115 @default.
• W2992887668 cites W2042010542 @default.
• W2992887668 cites W2054564814 @default.
• W2992887668 cites W2060789691 @default.
• W2992887668 cites W2073983790 @default.
• W2992887668 cites W2074706971 @default.
• W2992887668 cites W2083719502 @default.
• W2992887668 cites W2097984448 @default.
• W2992887668 cites W211424878 @default.
• W2992887668 cites W2121328463 @default.
• W2992887668 cites W2121790250 @default.
• W2992887668 cites W2133795831 @default.
• W2992887668 cites W2152600766 @default.
• W2992887668 cites W2312776009 @default.
• W2992887668 cites W2568322374 @default.
• W2992887668 cites W2602553973 @default.
• W2992887668 cites W2787494000 @default.
• W2992887668 cites W2939067612 @default.
• W2992887668 cites W2970991384 @default.
• W2992887668 doi "https://doi.org/10.1016/s2665-9913(19)30103-1" @default.
• W2992887668 hasPublicationYear "2020" @default.
• W2992887668 type Work @default.
• W2992887668 sameAs 2992887668 @default.
• W2992887668 citedByCount "10" @default.
• W2992887668 countsByYear W29928876682020 @default.
• W2992887668 countsByYear W29928876682021 @default.
• W2992887668 countsByYear W29928876682022 @default.
• W2992887668 countsByYear W29928876682023 @default.
• W2992887668 crossrefType "journal-article" @default.
• W2992887668 hasAuthorship W2992887668A5001117631 @default.
• W2992887668 hasAuthorship W2992887668A5006313543 @default.
• W2992887668 hasAuthorship W2992887668A5008926411 @default.
• W2992887668 hasAuthorship W2992887668A5010876723 @default.
• W2992887668 hasAuthorship W2992887668A5014431886 @default.
• W2992887668 hasAuthorship W2992887668A5018416006 @default.
• W2992887668 hasAuthorship W2992887668A5021039420 @default.
• W2992887668 hasAuthorship W2992887668A5025390498 @default.
• W2992887668 hasAuthorship W2992887668A5029122785 @default.
• W2992887668 hasAuthorship W2992887668A5037371315 @default.
• W2992887668 hasAuthorship W2992887668A5041345164 @default.
• W2992887668 hasAuthorship W2992887668A5052403064 @default.
• W2992887668 hasAuthorship W2992887668A5053880217 @default.
• W2992887668 hasAuthorship W2992887668A5057927354 @default.
• W2992887668 hasAuthorship W2992887668A5068116173 @default.
• W2992887668 hasAuthorship W2992887668A5073092807 @default.
• W2992887668 hasAuthorship W2992887668A5079776737 @default.
• W2992887668 hasAuthorship W2992887668A5083850527 @default.
• W2992887668 hasAuthorship W2992887668A5085246518 @default.
• W2992887668 hasConcept C112705442 @default.
• W2992887668 hasConcept C126322002 @default.
• W2992887668 hasConcept C142724271 @default.
• W2992887668 hasConcept C197934379 @default.
• W2992887668 hasConcept C204787440 @default.
• W2992887668 hasConcept C27081682 @default.
• W2992887668 hasConcept C2776715498 @default.
• W2992887668 hasConcept C2778375690 @default.
• W2992887668 hasConcept C2780841215 @default.
• W2992887668 hasConcept C71924100 @default.
• W2992887668 hasConcept C90924648 @default.
• W2992887668 hasConcept C98274493 @default.
• W2992887668 hasConceptScore W2992887668C112705442 @default.
• W2992887668 hasConceptScore W2992887668C126322002 @default.
• W2992887668 hasConceptScore W2992887668C142724271 @default.
• W2992887668 hasConceptScore W2992887668C197934379 @default.
• W2992887668 hasConceptScore W2992887668C204787440 @default.
• W2992887668 hasConceptScore W2992887668C27081682 @default.
• W2992887668 hasConceptScore W2992887668C2776715498 @default.

• next